Literature DB >> 3543091

Louis F. Bishop lecture. Role of coronary artery spasm in symptomatic and silent myocardial ischemia.

A Maseri.   

Abstract

The revival of the concept of coronary spasm has stimulated research into coronary artery disease. Observations in patients with variant angina have substantially contributed to the appreciation of painless myocardial ischemia. However, the presence or absence of pain during ischemic episodes is not related to the cause of ischemia, because painless ischemia can be observed in variant angina (caused by spasm), in effort-induced angina (caused by increased myocardial demand) and in myocardial infarction (caused by thrombosis). Continuous monitoring initially of patients with variant angina and subsequently of patients with unstable and stable angina proved that often painful and painless ischemic episodes are caused by a transient impairment of regional coronary blood flow rather than by an excessive increase of myocardial demand. The transient impairment of coronary flow appears to be caused by dynamic stenosis of epicardial coronary arteries. This most often occurs at the site of atherosclerotic plaques encroaching on the lumen to a variable extent. Dynamic stenosis can be caused by 1) "physiologic" increase of coronary tone, as in stable angina, 2) spasm, as in variant angina, and 3) thrombosis, usually in combination with "physiologic" changes in tone or with spasm, or both, as in unstable angina. The mechanisms of spasm, as typically observed in variant angina, are different from those of "physiologic" increase of tone; they appear to be related to a local alteration that makes a segment of coronary artery hyperreactive to a variety of constrictor stimuli causing only minor degrees of constriction in other coronary arteries. The nature of this abnormality, which may remain stable for months and years, is yet unknown.

Entities:  

Mesh:

Year:  1987        PMID: 3543091     DOI: 10.1016/s0735-1097(87)80372-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Rationale for treatment of silent myocardial ischemia: focus on nifedipine.

Authors:  R W Nesto
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Incremental diagnostic value of dipyridamole echocardiography and exercise thallium 201 scintigraphy in the assessment of presence and extent of coronary artery disease.

Authors:  V Di Bello; E Gori; C R Bellina; O Parodi; N Molea; G Santoro; G Mariani; U Conti; E Magagnini; P Marzullo
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

Review 3.  Antianginal actions of beta-adrenoceptor antagonists.

Authors:  Stephen T O'Rourke
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

4.  Diagnosis of coronary vasospasm by detection of postischemic regional left ventricular delayed relaxation using echocardiographic evaluation with color kinesis.

Authors:  Katsuhisa Ishii; Kunihisa Miwa; Toshinori Makita; Nobuaki Okuda; Takeshi Aoyama
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

5.  Asymptomatic ST-segment depression during exercise testing and the risk of sudden cardiac death in middle-aged men: a population-based follow-up study.

Authors:  Jari A Laukkanen; Timo H Mäkikallio; Rainer Rauramaa; Sudhir Kurl
Journal:  Eur Heart J       Date:  2009-01-23       Impact factor: 29.983

Review 6.  The pathological basis of angina pectoris.

Authors:  M J Davies
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 7.  Coronary Artery Vasospasm.

Authors:  Jae Kwan Song
Journal:  Korean Circ J       Date:  2018-09       Impact factor: 3.243

8.  Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory α7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm.

Authors:  Yen-Kuang Lin; Chi-Tai Yeh; Kuang-Tai Kuo; Iat-Hang Fong; Vijesh Kumar Yadav; Nicholas G Kounis; Patrick Hu; Ming-Yow Hung
Journal:  Oxid Med Cell Longev       Date:  2022-01-19       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.